Literature DB >> 2001136

Eosinophilia-myalgia syndrome. A clinical case series of 21 patients. New Mexico Eosinophilia-Myalgia Syndrome Study Group.

R M Philen1, M Eidson, E M Kilbourne, C M Sewell, R Voorhees.   

Abstract

We reviewed 21 cases of eosinophilia-myalgia syndrome to describe the range of clinical findings in these patients. Most patients were women (20 [95%]) and middle-aged (mean, 46 years) and had taken the food supplement L-tryptophan (95%). All cases involved eosinophilia (eosinophil count, greater than or equal to 2.0 x 10(9)/L) and incapacitating myalgias. Fourteen (88%) of the 16 patients tested had mild liver function abnormalities. Aldolase levels were abnormal in all patients tested. Muscle biopsies were done in five patients; four showed eosinophilic perimyositis, and one had interstitial inflammation. No physical finding was pathognomonic or universal, but muscle tenderness, tachycardia, and rash were the most common signs found during physical examinations. Seven patients were treated with prednisone, and six showed improvement in muscle pain and a decrease in eosinophilia. The cause of this disorder is still unknown.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2001136     DOI: 10.1001/archinte.151.3.533

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  Tryptophan. Current status and future trends for oral administration.

Authors:  L D Kaufman; R M Philen
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

2.  Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.

Authors:  F Sato; Y Hagiwara; Y Kawase
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

3.  Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats.

Authors:  L A Love; J I Rader; L J Crofford; R B Raybourne; M A Principato; S W Page; M W Trucksess; M J Smith; E M Dugan; M L Turner
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

4.  Eosinophilic hepatitis: a new feature of the clinical spectrum of the eosinophilia-myalgia syndrome.

Authors:  P Martinez-Osuna; C G Espinoza; M L Cuellar; G E Cabrera; L H Silveira; L R Espinoza
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

5.  The use of an elevated aldolase in diagnosing and managing eosinophilic fasciitis.

Authors:  Jennifer Nashel; Virginia Steen
Journal:  Clin Rheumatol       Date:  2014-09-24       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.